BiotechTube

MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoarthritis of Knee

Conditions

Osteoarthritis of Knee

Trial Timeline

Dec 22, 2020 → Aug 10, 2022

NCT ID
NCT04506463

About MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo

MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo is a phase 2 stage product being developed by Sun Pharmaceutical for Osteoarthritis of Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT04506463. Target conditions include Osteoarthritis of Knee.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04506463Phase 2Completed

Competing Products

20 competing products in Osteoarthritis of Knee

See all competitors
ProductCompanyStageHype Score
Duloxetine + PlaceboEli LillyPhase 3
77
LY2828360 + PlaceboEli LillyPhase 2
52
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
77
Duloxetine + Sugar pillEli LillyApproved
85
UBX0101 or placeboUnity BiotechnologyPre-clinical
15
UBX0101Unity BiotechnologyPhase 1
25
UBX0101Unity BiotechnologyPhase 2
44
UBX0101Unity BiotechnologyPhase 1
25
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
52
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
77
ASP7962 + Naproxen + PlaceboAstellas PharmaPhase 2
52
Capsaicin Topical SolutionAstellas PharmaApproved
85
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
52
Duloxetine + PlaceboShionogiPhase 3
77
DuloxetineShionogiPhase 3
77
ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part DOno PharmaceuticalPhase 1
33
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
52
Duloxetine + PlaceboEli LillyPhase 3
77
LY3556050 + PlaceboEli LillyPhase 2
52
Eloralintide + PlaceboEli LillyPhase 3
77

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85